Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.51 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112229 | 0.88 | F10 (0.49) | F10 | |
| SCHEMBL5632397 | 0.85 | F10 (0.58) | F10F2ELANE | |
| SCHEMBL2951356 | 0.75 | LNPEP (0.48) | F10 | |
| SCHEMBL23213657 | 0.75 | USP30 (0.50) | — | |
| SCHEMBL29796156 | 0.75 | USP30 (0.50) | — | |
| SCHEMBL10260514 | 0.74 | HTR1F (0.52) | F2 | |
| SCHEMBL1456142 | 0.73 | CKS1B (0.54) | — | |
| SCHEMBL5632535 | 0.73 | F10 (0.49) | F10F2ELANE | |
| Hydrochloric Acid SCHEMBL4504668 | 0.73 | HTR1F (0.51) | F2 | |
| SCHEMBL6580787 | 0.72 | GHSR (0.48) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | F2, SERPINC1, F11 | F10 8/4885F2 1/4885ELANE 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.